Brief: Cardiff Oncology Announces First Patient Dosed In Randomized First-Line Ras-Mutated Metastatic Colorectal Cancer Trial
29/02/2024 22:45
Feb 29 (Reuters) - Cardiff Oncology Inc CRDF.O :
* CARDIFF ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN
RANDOMIZED
FIRST-LINE RAS-MUTATED METASTATIC COLORECTAL CANCER TRIAL
(CRDF-004)
* CARDIFF ONCOLOGY INC - PHASE 2 TRIAL IN PATIENTS WITH
RAS-MUTATED MCRC WILL EVALUATE ONVANSERTIB PLUS SOC VERSUS SOC
ALONE IN FIRST-LINE SETTING
* CARDIFF ONCOLOGY INC - PFIZER IGNITE IS RESPONSIBLE FOR
CLINICAL
EXECUTION OF TRIAL
* CARDIFF ONCOLOGY INC - INITIAL TOPLINE RESULTS EXPECTED IN
MID-2024
Source text for Eikon: ID:nGNX64CmX8
Further company coverage: CRDF.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering